Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
Saito
Mitsue
M
Juntendo University - Breast Oncology, 3-1-3 Hongo Bunkyo-ku, Tokyo 113- 8431, Japan. mitsue@juntendo.ac.jp
Tsukuda
Mamoru
M
D000818:Animals; D000932:Antiemetics / Q000009:adverse effects / Q000266:history / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000266:history / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000266:history / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D000077924:Palonosetron; D011812:Quinuclidines / Q000009:adverse effects / Q000266:history / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058831:Serotonin 5-HT3 Receptor Antagonists; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D018492:Dopamine Antagonists; D007546:Isoquinolines; D011812:Quinuclidines; D058831:Serotonin 5-HT3 Receptor Antagonists; D000077924:Palonosetron